tbuckley/cabot-search huggingface dataset:
Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer
Authors: Geoffrey R. Oxnard, Cloud P. Paweletz, Lynette M. Sholl
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Five minutes with . . . Frank Atherton, chief medical officer for Wales
Authors: Abi Rimmer
Journal: BMJ (2016)

The former deputy chief medical officer for Nova Scotia discusses his new role in the UK

“Wales and Nova Scotia are very similar in many ways. Nova Scotia has a big geographical area, so it faces the same issues around providing health services and improving health in remote rural areas.

“There was a lot of steel and coal mining in Nova Scotia. Those industries have gone, so communities …
LAW AND MEDICINE
Authors: James J. McNamara
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparing the SPRINT and the HOPE-3 Blood Pressure Trial
Authors: Paul K. Whelton, David M. Reboussin, Lawrence J. Fine
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Comparison of pharmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma.
Authors: I. Poddubnaya, L. Babicheva, K. Kaplanov, Andrey Zaritskey, E. Volodicheva, S. Alexeev, A. Loginov, R. Orlova, V. Dvornichenko, Oleg Gladkov, M. Kosinova, O. Serduk, V. Milovanov, A. Myasnikov, Attili Venkatasatya Suresh, Minish Jain, S. Patil, Senthil Jagannathan Rajappa, R. Ivanov, E. Chernyaeva
Journal: Journal of Clinical Oncology (2014)

e19545^ Background: BCD-020 is a rituximab biosimilar candidate with high level of similarity to innovator rituximab (RTX) shown in non-clinical studies. Comparative clinical study in patients with low-grade B-cell NHL was carried out to prove comparability of pharmacokinetics (PK) and pharmacodynamics (PD) in humans. Methods: the study enrolled 92 patients with CD20-positive fNHL, stage II-IV, 1-2 histologic grade, or SMZL, who were randomised in 1:1 ratio to receive 375 mg/sq.m of BCD-020 or RTX on days 1,8,15 and 22. Serum samples for PK assessment were drawn at 0, 24, 48, 72 hours after the first infusion of rituximab, prior infusion on days 8, 15, 22 and at the end of study on day 50. Whole blood for evaluation of PD was collected at the same time points. Results: 72 patients with fNHL were included into the study (35 patients in BCD-020 arm, 37 – in RTX arm) as well as 20 patients with SMZL (11 patients and 9 patients, respectively). The sustained depletion of CD19-positive cells developed during the first week after a single infusion of BCD-020 or RTX without statistically significant differences. 90% CI for the geometric mean of a BCD-020/RTX AUC0-t ratio fell within standard bioequivalence range 80-125% (80.1-118.2% for the ratio of AUC0-168 after a single dose and 81.2-124.8% for the ratio of AUC0-1176 after 4 doses). There were equal number of AEs in two arms; 78 AEs in BCD-020 arm and 73 AEs in RTX arm (majority of them were mild/moderate, there were just 4 grade 3-4 AEs in each arm). 2 SAEs were reported in RTX-arm. Binding antibodies against rituximab were found in 2 patients treated with RTX. Conclusions: BCD-020 is equivalent to RTX in terms of PK; both medicines have comparable PD and safety profile. Clinical trial information: NCT01701232.
A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients
Authors: Mingjia Li, Aziz Nazha, Paul Elson, Sean Hobson, Mikkael A. Sekeres, Matt E. Kalaycio, Ronald M. Sobecks, Aaron Gerds, Betty K. Hamilton, Sudipto Mukherjee, Hetty E. Carraway, Anjali S. Advani
Journal: Blood (2014)
Rare HFE variants are the most frequent cause of hemochromatosis in non‐c282y homozygous patients with hemochromatosis
Authors: Houda Hamdi‐Rozé, Marie‐Pascale Beaumont‐Epinette, Zeineb Ben Ali, Caroline Le Lan, Véronique Loustaud‐Ratti, Xavier Causse, Olivier Loreal, Yves Deugnier, Pierre Brissot, Anne‐Marie Jouanolle, Edouard Bardou‐Jacquet
Journal: American Journal of Hematology (2016)

p.Cys282Tyr (C282Y) homozygosity explains most cases of HFE ‐related hemochromatosis, but a significant number of patients presenting with typical type I hemochromatosis phenotype remain unexplained. We sought to describe the clinical relevance of rare HFE variants in non‐C282Y homozygotes. Patients referred for hemochromatosis to the National Reference Centre for Rare Iron Overload Diseases from 2004 to 2010 were studied. Sequencing was performed for coding region and intronic flanking sequences of HFE, HAMP, HFE2, TFR2, and SLC40A1 . Nine private HFE variants were identified in 13 of 206 unrelated patients. Among those, five have not been previously described: p.Leu270Argfs*4, p.Ala271Valfs*25, p.Tyr52*, p.Lys166Asn, and p.Asp141Tyr. Our results show that rare HFE variants are identified more frequently than variants in the other genes associated with iron overload. Rare HFE variants are therefore the most frequent cause of hemochromatosis in non‐C282Y homozygote HFE patients. Am. J. Hematol. 91:1202–1205, 2016. © 2016 Wiley Periodicals, Inc.
Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo
Authors: Clasina M. Venema, Giulia Apollonio, Geke A.P. Hospers, Carolina P. Schröder, Rudi A.J.O. Dierckx, Erik F.J. de Vries, Andor W.J.M. Glaudemans
Journal: Clinical Nuclear Medicine (2016)

The estrogen derivative 16α-F-fluoro-17β-estradiol (FES) is a PET tracer that has been used in a variety of preclinical and clinical studies to detect estrogen receptor (ER) expression, mainly in breast cancer, but also for other oncological indications. As a result of the success of these studies and the potential applications of the tracer, FES starts to be implemented in routine clinical practice. However, the number of centers using this tracer is still limited and many nuclear medicine physicians and medical oncologists are still unaware of the possibilities FES PET imaging offers. The aim of this article is therefore to give an overview of the main indications of FES PET in oncology and to provide recommendations on correct use of this imaging technique. This includes precautions that have to be taken for patient preparation, procedures for the acquisition of the scans, the physiological distribution of the tracer, factors that might influence tracer uptake and guidance for image analysis, quantification of tracer uptake, and reporting of the scans.
Metabolomic Profiles Reveal Sphingosine-1-Phosphate As a Novel Allosteric Modulator of Hemoglobin-Oxygen Affinity and a Key Contributor to Pathophysiology of Sickle Cell Disease
Authors: Yujin Zhang, Vladimir Berka, Wei Wang, Weiru Zhang, Chen Ning, Kaiqi Sun, Danny C Alexander, Michael Milburn, Mostafa Ahmed, Modupe Idowu, Rodney E. Kellems, Jun Zhang, Martin Safo, Ah-lim Tsai, Harinder S. Juneja, Yang Xia
Journal: Blood (2011)
Soy Formula and Epigenetic Modifications: Analysis of Vaginal Epithelial Cells from Infant Girls in the IFED Study
Authors: Sophia Harlid, Margaret Adgent, Wendy N. Jefferson, Vijayalakshmi Panduri, David M. Umbach, Zongli Xu, Virginia A. Stallings, Carmen J. Williams, Walter J. Rogan, Jack A. Taylor
Journal: Environmental Health Perspectives (2016)

Early-life exposure to estrogenic compounds affects the development of the reproductive system in rodent models and humans. Soy products, which contain phytoestrogens such as genistein, are one source of exposure in infants fed soy formula, and they result in high serum concentrations.Our goal was to determine whether soy exposure is associated with differential DNA methylation in vaginal cells from soy-fed infant girls.Using the Illumina HumanMethylation450 BeadChip, we evaluated epigenome-wide DNA methylation in vaginal cells from four soy formula-fed and six cow formula-fed girls from the Infant Feeding and Early Development (IFED) study. Using pyrosequencing we followed up the two most differentially methylated sites in 214 vaginal cell samples serially collected between birth and 9 months of age from 50 girls (28 soy formula-fed and 22 cow formula-fed). With a mouse model, we examined the effect of neonatal exposure to genistein on gene specific mRNA levels in vaginal tissue.The epigenome-wide scan suggested differences in methylation between soy formula-fed and cow formula-fed infants at three CpGs in the gene proline rich 5 like (PRR5L) (p < 104). Pyrosequencing of the two feeding groups found that methylation levels progressively diverged with age, with pointwise differences becoming statistically significant after 126 days. Genistein-exposed mice showed a 50% decrease in vaginal Prr5l mRNA levels compared to controls.Girls fed soy formula have altered DNA methylation in vaginal cell DNA which may be associated with decreased expression of an estrogen-responsive gene. Citation: Harlid S, Adgent M, Jefferson WN, Panduri V, Umbach DM, Xu Z, Stallings VA, Williams CJ, Rogan WJ, Taylor JA. 2017. Soy formula and epigenetic modifications: analysis of vaginal epithelial cells from infant girls in the IFED study. Environ Health Perspect 125:447-452; http://dx.doi.org/10.1289/EHP428.
Abstract P1-14-20: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)
Authors: Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Jo Anne Zujewski, Robert Justice, Sibylle Loibl, Lawrence Wickerham, Jan Bogaerts, Jose Baselga, Charles Perou, Gideon Blumenthal, Jens Blohmer, Eleftherios Mamounas, Jonas Bergh, Vladimir Semiglazov, Tatiana Prowell, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter Fasching, Sandra M Swain, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, Wolfgang Eiermann, Gunter von Mincwitz
Journal: Cancer Research (2012)

Abstract Withdrawn by Author Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-14-20.
Recurrent Aortic Dissection
Authors: Eric M. Isselbacher, Marc P. Bonaca, Marco Di Eusanio, James Froehlich, Eduardo Bossone, Udo Sechtem, Reed Pyeritz, Himanshu Patel, Ali Khoynezhad, Hans-Henning Eckstein, Guillaume Jondeau, Fabio Ramponi, Mohammad Abbasi, Daniel Montgomery, Christoph A. Nienaber, Kim Eagle, Mark E. Lindsay
Journal: Circulation (2016)

Improved medical care after initial aortic dissection (AD) has led to increased survivorship and a population of individuals at risk for further cardiovascular events, including recurrent AD. Reports describing recurrent ADs have been restricted to small numbers of patients from single institutions. We used the IRAD (International Registry of Acute Aortic Dissection) database to examine the clinical profiles and outcomes of patients with recurrent AD.We identified 204 patients enrolled in IRAD with recurrent AD. For the primary analysis, patient characteristics, interventions, and outcomes were analyzed and compared with 3624 patients with initial AD. Iterative logistic modeling was performed to investigate variables associated with recurrent AD. Cox regression analyses were used to determine variables associated with 5-year survival. A subset of recurrent AD patients was analyzed for anatomic and demographic details of initial and recurrent ADs.Patients with recurrent AD were more likely to have Marfan syndrome (21.5% versus 3.1%; P<0.001) but not bicuspid aortic valve (3.6% versus 3.2%; P=0.77). Descending aortic dimensions were greater in patients with recurrent AD than in patients with initial AD independently of sentinel dissection type (type A: 4.3 cm [3.5-5.6 cm] versus 3.3 cm [2.9-3.7 cm], P<0.001; type B: 5.0 cm [3.9-6.0 cm] versus 4.0 cm [3.5-4.8 cm], P<0.001), and this observation was accentuated among patients with Marfan syndrome. In multivariate analysis, the diagnosis of Marfan syndrome independently predicted recurrent AD (hazard ratio, 8.6; 95% confidence interval, 5.8-12.8; P<0.001). Patients with recurrent AD who presented with proximal followed by distal AD were younger than patients who experienced distal followed by proximal dissection AD (42.1±16.1 versus 54.3±14.8 years; P=0.004).Among those suffering acute aortic dissection, 5% have a history of a prior aortic dissection. Recurrent AD is strongly associated with Marfan syndrome.
Optical Coherence Tomography Angiography Vessel Density in Glaucomatous Eyes with Focal Lamina Cribrosa Defects
Authors: Min Hee Suh, Linda M. Zangwill, Patricia Isabel C. Manalastas, Akram Belghith, Adeleh Yarmohammadi, Felipe A. Medeiros, Alberto Diniz-Filho, Luke J. Saunders, Siamak Yousefi, Robert N. Weinreb
Journal: Ophthalmology (2016)
Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
Authors: Gabor Kovacs, Jasmin Bahlo, Sandra Kluth, Paula Cramer, Anna-Maria Fink, Kirsten Fischer, Carolin Gross-Ophoff-Mueller, Petra Langerbeins, Christian Maurer, Julia von Tresckow, Clemens-Martin Wendtner, Stephan Stilgenbauer, Michael Hallek, Barbara Eichhorst, Valentin Goede
Journal: Blood (2015)
Tolerability of different first-line treatment (trt) regimens in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).
Authors: L. Müller, A. Münch, K. Blumenstengel, U. Hutzschenreuther, S. Busies
Journal: Journal of Clinical Oncology (2010)

e15086 Background: Trt of mRCC pts has been substantially improved by approval of sunitinib, sorafenib, temsirolimus and bevacizumab. Little is known so far concerning the tolerability in daily practice. The aim of this study is to evaluate these trt regimens in clinical practice. Methods: A total of 250 pts with mRCC who had stopped 1st line therapy during the years 2008-2009 in 100 centers in Germany were included in the present study from a larger prospective German RCC registry being conducted by iOMEDICO. Inclusion Criteria were: 1) Pts with metastatic or locally advanced RCC requiring therapy 2) Start of 1st palliative therapy within 1 year before enrolment 3) Age at least 18 years 4) Informed written consent. Out of 450 pts the first 250 pts—in order of recruitment—who had stopped 1st line therapy due to progression, toxicities, death or loss to follow-up were selected. Cut-off date was November 15th 2009. Data had been recorded prospectively for these pts for demographic/clinical characteristics, trt-decisions, tolerability and clinical outcomes by German oncologists and urologists. Results: More of the pts were male (63.2%); many were >60 years of age (70.8%). Sunitinib was given most often (60.4%), followed by temsirolimus (14%), interferon (12.4%), sorafenib (10.0%) and bevacizumab (5.6%). 1.6% of pts received interleukin-2. Dose reductions due to toxicities were documented in 29.8% of pts treated with sunitinib, 28% with sorafenib, 3.2% with interferon, 2.9% with temsirolimus. Across agents, the most common toxicities (all grade) were documented as gastrointestinal (GI) (36.8%), followed by dermatology/skin and constitutional symptoms (CS), each at 19.6% Most common gastrointestinal (GI) disorders were diarrhea (11.2%), nausea (9.2%) and vomiting (6.8%). A prominent CS was fatique (14%). For sunitinb, the most often used therapy (N=151 pts), the most common toxicities were GI (47.7%), followed by blood/bone marrow (21.1%), CS (19.2%), and dermatology/skin (17.2%). Conclusions: In clinical practice the trts were associated with a large number of adverse events necessitating trt modifications, and providing evidence for the need for additional trt options. No significant financial relationships to disclose.
Effect of US Food and Drug Administration–Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting
Authors: Jing Xu, Rajdeep Gill, Marisa Cruz, Judy Staffa, Peter Lurie
Journal: JAMA Pediatrics (2016)

This study examined the effect of pediatric labeling for OxyContin on dispensing of all extended-release oxycodone products, using national data on dispensed prescriptions in outpatient retail pharmacies before and after the label change.
Headline-Grabbing Study Brings Attention Back to Medical Errors
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Self‐Assembling Doxorubicin Prodrug Forming Nanoparticles and Effectively Reversing Drug Resistance In Vitro and In Vivo
Authors: Xiaoman Mao, Jingxing Si, Qian Huang, Xuanrong Sun, Qianzhi Zhang, Youqing Shen, Jianbin Tang, Xiangrui Liu, Meihua Sui
Journal: Advanced Healthcare Materials (2016)

Doxorubicin (DOX) is a widely used chemotherapeutic drug to treat a range of cancers. However, its unfavorable effects, particularly the cardiotoxicity and the induction of multidrug resistance (MDR), significantly limit its clinical applications. Herein, a novel doxorubicin prodrug, PEG2K -DOX, is synthesized by conjugating a deprotonated doxorubicin molecule with the polyethylene glycol (PEG, MW: 2K) chain via pH-responsive hydrazone bond, and its potential as a better alternative than doxorubicin is evaluated. The data show that the amphiphilic PEG2K -DOX can self-assemble into stable nanoparticles with a high and fixed doxorubicin loading content (≈20 wt%), a favorable size of 91.5 nm with a narrow polydispersity (PDI = 0.14), good stability, and pH-dependent release behavior due to the acid-cleavable linkage between PEG and doxorubicin. Although doxorubicin hardly accumulates in MDR cells, PEG2K -DOX nanoparticles significantly increase the cellular uptake and cell-killing activity of doxorubicin in two MDR cancer cell lines MCF-7/ADR and KBv200, with the IC50 values dropped to 1.130% and 42.467% of doxorubicin, respectively. More impressively, PEG2K -DOX nanoparticles exhibit significantly improved plasma pharmacokinetics, increased in vivo therapeutic efficacy against MDR xenograft tumors, and better in vivo safety compared with doxorubicin. PEG2K -DOX nanoparticles hold the promise to become a better alternative than doxorubicin for cancer treatment, especially for MDR tumors.